Correction to: MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma (BMC Cancer, (2012), 12, 1, (546), 10.1186/1471-2407-12-546);MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Cui, Li ^a   Zhou, Hua ^a   Zhao, Hu ^b   Zhou, Yaojun ^a   Xu, Renfang ^a   Xu, Xianlin ^a   Zheng, Lu ^a   Xue, Zhong ^a   Xia, Wei ^a   Zhang, Bo ^a   Ding, Tao ^a   Cao, Yunjie ^a   Tian, Zinong ^a   Shi, Qianqian ^a   He, Xiaozhou ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b JIANGYIN PEOPLE S HOSPITAL   (China)

Author keywords

MicroRNA 99a; mTOR; Renal cell carcinoma

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 99A; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84869885702     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-021-07839-z     Document Type: Erratum

References (32)

1. White NM, Yousef GM. MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer. BMC Med 2010, 8:65. 10.1186/1741-7015-8-65, 2978114, 20964839.
2. van Spronsen DJ, de Weijer KJ, Mulders PF, De Mulder PH. Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs 2005, 16(7):709-717. 10.1097/01.cad.0000167901.58877.a3, 16027518.
3. Pascual D, Borque A. Epidemiology of kidney cancer. Adv Urol 2008, 2008:782381.
4. Reeves DJ, Liu CY. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2009, 64(1):11-25. 10.1007/s00280-009-0983-z, 19343348.
5. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30(4):843-852. 10.1016/S0094-0143(03)00056-9, 14680319.
6. Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R, Pace KT, Yousef GM. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2010, 43(1-2):150-158.
7. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder H, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007, 26(28):4148-4157. 10.1038/sj.onc.1210186, 17260024.
8. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008, 27(45):5959-5974. 10.1038/onc.2008.274, 18836476.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866. 10.1038/nrc1997, 17060945.
10. Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, Hu C, Zhang L. Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol 2009, 35(10):1119-1123. 10.1016/j.ejso.2009.04.010, 19443172.
11. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer Metastasis Rev 2009, 28(3-4):369-378.
12. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009, 27(34):5848-5856. 10.1200/JCO.2009.24.0317, 2793003, 19884536.
13. Nagayama K, Kohno T, Sato M, Arai Y, Minna JD, Yokota J. Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer 2007, 46(11):1000-1010. 10.1002/gcc.20485, 17674361.
14. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008, 14(9):2690-2695. 10.1158/1078-0432.CCR-07-1731, 18451233.
15. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008, 14(9):2588-2592. 10.1158/1078-0432.CCR-07-0666, 18451220.
16. Gao W, Shen H, Liu L, Xu J, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011, 137(4):557-566. 10.1007/s00432-010-0918-4, 20508945.
17. Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 2011, 286(42):36677-36685. 10.1074/jbc.M111.270561, 3196113, 21878637.
18. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larre S, Milo M, Rehman I, Rosario DJ, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 2009, 69(21):8472-8481. 10.1158/0008-5472.CAN-09-0744, 2871298, 19843843.
19. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, Jensen RV, Moskaluk CA, Dutta A. miR-99 family of microRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 2011, 71(4):1313-1324. 10.1158/0008-5472.CAN-10-1031, 21212412.
20. Doghman M, El WA, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del VM, Figueiredo BC, Zambetti GP, Lalli E. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 2010, 70(11):4666-4675. 10.1158/0008-5472.CAN-09-3970, 2880211, 20484036.
21. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004, 24(1):200-216. 10.1128/MCB.24.1.200-216.2004, 303352, 14673156.
22. Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999, 59(15):3581-3587.
23. Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, Morii E, Okumura M, Aozasa K, Okada M. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 2011, 30(32):3489-3501. 10.1038/onc.2011.63, 21383697.
24. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2007, 96(Suppl):R11-R15.
25. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007, 12(1):9-22. 10.1016/j.ccr.2007.05.008, 17613433.
26. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005, 16(4):525-537. 10.1093/annonc/mdi113, 15728109.
27. Kapoor A. Inhibition of mTOR in kidney cancer. Curr Oncol 2009, 16(Suppl 1):S33-S39. 2687803, 19478899.
28. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27(Suppl 2):S43-S51.
29. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010, 24(2):447-463. 10.1210/me.2009-0295, 2817607, 20081105.
30. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L, Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010, 70(12):5184-5193. 10.1158/0008-5472.CAN-10-0145, 20501828.
31. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010, 46(2):298-311. 10.1016/j.ejca.2009.10.027, 19948396.
32. Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, Osada H, Nagino M, Takahashi T. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chromosomes Cancer 2008, 47(9):810-818. 10.1002/gcc.20582, 18523997.